Hot Water Below Target in a Bone Marrow Transplant Unit
A 240-bed acute-care hospital completed its water management program 18 months ago. During the annual hazard review, the team finds hot water at the sixth-floor bone marrow transplant (BMT) unit reaches only 44-47 degrees C at distal shower outlets, while the basement water heater is set to 60 degrees C. A wing vacated in 2019 leaves six dead legs on the sixth floor. Cold water in the pharmacy reaches 24 degrees C in summer. Two of eight BMT outlets sampled grew Legionella pneumophila serogroup 1 at 300 and 60 CFU/mL; no cases have been identified in 12 months. The facilities director proposes replacing the water heater and rechecking next year because there are no cases.
1. Critique the facilities director's proposal against hazard analysis and risk assessment expectations. What is wrong with the reasoning?
Read the worked answer
The proposal fails on four counts
- Absence of cases is not evidence of control. BMT patients are among the highest-risk groups; surveillance is insensitive because legionellosis is underdiagnosed and the look-back period is short. Detection of serogroup 1 at 300 CFU/mL in a protected population is itself an actionable hazard signal under most program action levels.
- The root cause is misdiagnosed. The heater is already at 60 degrees C; the problem is distribution and recirculation, mixing-valve behavior, heat loss, and stagnation from dead legs. Replacing the heater would not change the 44-47 degrees C distal readings.
- Multiple hazards are ignored. Cold water at 24 degrees C and six dead legs are independent growth risks that the hazard analysis should have flagged.
- Deferral conflicts with the program. Corrective action, verification of effectiveness, and documentation are required when a control limit is exceeded; rechecking in a year is not a corrective action.
What should happen: reconvene the team with infection prevention, revise the risk assessment, and document interim risk-reduction measures for the BMT unit while permanent fixes are designed.
2. Sequence the corrective actions into 24-hour, 7-day, and 30-day buckets, and justify the ordering.
Read the worked answer
Ordering principle: protect the highest-risk patients first, then remove growth conditions, then confirm by measurement.
Within 24 hours
- Restrict or filter BMT showers (point-of-use 0.2 micron filters) and use an alternative bathing method; do not rely on temperature alone.
- Notify infection prevention and review pneumonia surveillance, including Legionella testing for BMT patients with pneumonia.
- Begin engineering correction of hot water: restore storage at 60 degrees C or above and return temperature at 49 degrees C or above, checking mixing valves and recirculation balance.
Within 7 days
- Remove or cap the six dead legs properly, flush the affected branch, and disinfect the sixth-floor system (thermal or chlorinated shock per program procedure).
- Resample outlets after disinfection, using the same method as the original samples.
Within 30 days
- Address cold water at the pharmacy (loop treatment, flushing, insulation, or point-of-use control).
- Document corrective actions, verification results, and revised monitoring frequency; re-validate with surveillance data after a defined period.
3. How should the team distinguish verification from validation here, and what metrics would show the program is working?
Read the worked answer
Verification answers: did we do what the plan says?
- Distal temperatures recorded on schedule, chlorine or other residual logs complete, dead legs removed and documented, corrective actions closed with signatures, resample results attached.
- If temperatures were never recorded at distal outlets, verification was already failing before the findings.
Validation answers: does the program actually control the hazard?
- Environmental outcome: Legionella prevalence and concentration in BMT outlets at or below the program action level over repeated rounds.
- Clinical outcome: no healthcare-associated Legionnaires' disease, supported by active surveillance with culture and urine antigen testing for pneumonia in BMT patients, over a defined observation period.
Practical metrics: percentage of monitoring rounds completed on time, percentage of corrective actions verified effective within 30 days, number of outlets above action level, and number of healthcare-associated cases. A single negative resample is verification evidence, not validation; validation requires sustained environmental and clinical results.